Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 11/2014

01-11-2014 | Cardiovascular Infections (D Levine, Section Editor)

The Role of Hemostasis in Infective Endocarditis

Authors: Emanuele Durante-Mangoni, Rosa Molaro, Domenico Iossa

Published in: Current Infectious Disease Reports | Issue 11/2014

Login to get access

Abstract

Infective endocarditis (IE) is a thromboinflammatory disease of the endocardium, with pathophysiology mostly the result of the interplay between microorganisms and modifiers of the hemostasis system. In this setting, the evidence gathered so far warrants a more systematic appraisal. In this review article, experimental and clinical data on the role of hemostasis in IE are summarized. Starting from the current pathogenetic model of IE, we discuss the dual role of platelets in this condition, the microbial interaction with the hemostasis system, also describing nonspecific hemostasis changes during sepsis. We finally propose our hypothesis of thrombophilia as a possible trigger of IE, highlighting the challenges that the study of hemostasis in IE presents. The role of hemostasis in IE appears to be an exciting field of research. The activity of the hemostasis system is highly relevant in terms of susceptibility, progression, and treatment of IE. Pharmacologic modulation of hemostasis before and after IE onset is possible and represents still a largely unexplored area of study.
Literature
1.
Thiene G, Basso C. Pathology and pathogenesis of infective endocarditis in native heart valves. Cardiovasc Pathol. 2006;15(5):256–63.PubMedCrossRef
2.
3.
Moreillon P, Que YA, Bayer AS. Pathogenesis of streptococcal and staphylococcal endocarditis. Infect Dis Clin North Am. 2002;16:297–318.PubMedCrossRef
4.
Widmer E, Que YA, Entenza JM, et al. New concepts in the pathophysiology of infective endocarditis. Curr Infect Dis Rep. 2006;8:271–9.PubMedCrossRef
5.
Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost. 1997;77:408–23.PubMed
6.
7.
Ford I, Douglas CW. The role of platelets in infective endocarditis. Platelets. 1997;8(5):285–94.PubMedCrossRef
8.
Kiefer TL, Bashore TM. Infective endocarditis: a comprehensive overview. Rev Cardiovasc Med. 2012;13(2/3):e105–20.PubMed
9.
Rohmann S, Erbel R, Gorge G, et al. Prediction of rapid versus prolonged healing of infective endocarditis by monitoring vegetation size. J Am Soc Echocardiogr. 1991;4:465–74.PubMedCrossRef
10.
Rohmann S, Erbel R, Gorge G, et al. Clinical relevance of vegetation localization by transesophageal echocardiography in infective endocarditis. Eur Heart J. 1992;13:446–52.PubMed
11.
Sakariasse KS, Holme PA, et al. Shear-induced platelet activation and platelet microparticle formation in native human blood. Thromb Res. 1998;92:S33–43.CrossRef
12.
Girdhar G, Bluestein D. Biological effects of dynamic shear stress in cardiovascular pathologies and devices. Expert Rev Med Devic. 2008;5(2):167–81.CrossRef
13.•
Vanassche T, Peetermans WE, Herrgods MC, Herijgers P, Verhamme P. Anti-thrombotic therapy in infective endocarditis. Expert Rev Cardiovasc Ther. 2011;9(9):1203–19. This review comprehensively summarizes the current evidence on the pharmacologic modulation of the hemostasis system in infective endocarditis.PubMedCrossRef
14.
Patti JM, Allen BL, MecGavin MJ, Hook M. MSCRAMM-mediated adherence of microorganism to host tissues. Annu Rev Microbiol. 1994;48:585–617.PubMedCrossRef
15.
François P, Vaudaux P, Lew PD. Role of plasma and extracellular matrix proteins in the physiopathology of foreign body infections. Ann Vasc Surg. 1998;12(1):34–40.PubMedCrossRef
16.
Johnson CM, Bowie EJ. Pigs with von Willebrand disease may be resistant to experimental infective endocarditis. J Lab Clin Med. 1992;120(4):553–8.PubMed
17.
Sullam PM, Bayer AS, Foss WM, Cheung AL. Diminished platelet binding in vitro by Staphylococcus aureus is associated with reduced virulence in a rabbit model of infective endocarditis. Infect Immun. 1996;64(12):4915–21.PubMedPubMedCentral
18.
Yeaman MR. The role of platelets in antimicrobial host defense. Clin Infect Dis. 1997;25(5):951–68.PubMedCrossRef
19.
Bayer AS, Bolger AF, Taubert KA, et al. Diagnosis and management of infective endocarditis and its complication. Circulation. 1998;98:2936–28.PubMedCrossRef
20.
Yeaman MR, Norman DC, Bayer AS. Platelet microbicidal protein enhances antibiotic-induced killing of and postantibiotic effect in Staphylococcus aureus. Antimicrob Agents Chemother. 1992;36(8):1665–70.PubMedCrossRefPubMedCentral
21.
Yeaman MR, Norman DC, Bayer AS. Staphylococcus aureus susceptibility to thrombin-induced platelet microbicidal protein is independent of platelet adherence and aggregation in vitro. Infect Immun. 1992;60(6):2368–74.PubMedPubMedCentral
22.
Yeaman MR, Sullam PM, Dazin PF, Bayer AS. Platelet microbicidal protein alone and in combination with antibiotics reduces Staphylococcus aureus adherence to platelets in vitro. Infect Immun. 1994;62(8):3416–23.PubMedPubMedCentral
23.
Yeaman MR, Tang YQ, Shen AJ, Bayer AS, Selsted ME. Purification and in vitro activities of rabbit platelet microbicidal proteins. Infect Immun. 1997;65(3):1023–31.PubMedPubMedCentral
24.
25.•
Kupferwasser LI, Yeaman MR, Shapiro SM, Nast CC, Bayer AS. In vitro susceptibility to thrombin-induced platelet microbicidal protein is associated with reduced disease progression and complication rates in experimental Staphylococcus aureus endocarditis: microbiological, histopathologic, and echocardiographic analyses. Circulation. 2002;105(6):746–52. This study elegantly describes the antimicrobial effects of platelet-derived proteins.PubMedCrossRef
26.
Dankert J, Krijgsveld J, van Der Werff J, Joldersma W, Zaat SA. Platelet microbicidal activity is an important defense factor against viridans streptococcal endocarditis. J Infect Dis. 2001;184(5):597–605.PubMedCrossRef
27.
Patti JM, Höök M. Microbial adhesins recognizing extracellular matrix macromolecules. Curr Opin Cell Biol. 1994;6(5):752–8.PubMedCrossRef
28.
29.
Flock JI, Fröman G, Jönsson K, Guss B, Signäs C, Nilsson B, et al. Cloning and expression of the gene for a fibronectin-binding protein from Staphylococcus aureus. EMBO J. 1987;6(8):2351–7.PubMedPubMedCentral
30.
Fröman G, Switalski LM, Speziale P, Höök M. Isolation and characterization of a fibronectin receptor from Staphylococcus aureus. J Biol Chem. 1987;262(14):6564–71.PubMed
31.
Signäs C, Raucci G, Jönsson K, Lindgren PE, Anantharamaiah GM, Höök M, et al. Nucleotide sequence of the gene for a fibronectin-binding protein from Staphylococcus aureus: use of this peptide sequence in the synthesis of biologically active peptides. Proc Natl Acad Sci U S A. 1989;86(2):699–703.PubMedCrossRefPubMedCentral
32.
Jönsson K, Signäs C, Müller HP, Lindberg M. Two different genes encode fibronectin binding proteins in Staphylococcus aureus. The complete nucleotide sequence and characterization of the second gene. Eur J Biochem. 1991;202(3):1041–8.PubMedCrossRef
33.
Peacock SJ, Foster TJ, Cameron BJ, Berendt AR. Bacterial fibronectin-binding proteins and endothelial cell surface fibronectin mediate adherence of Staphylococcus aureus to resting human endothelial cells. Microbiology. 1999;145(Pt 12):3477–86.PubMed
34.
Que YA et al. Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. J Exp Med. 2005;201:1627–35.PubMedCrossRefPubMedCentral
35.
Sinha B, Francois PP, Nusse O, Foti M, Hartford OM, Vaudaux P, et al. Fibronectin-binding protein acts as Staphylococcus aureus invasin via fibronectin bridging to integrin alpha5beta1. Cell Microbiol. 1999;1(2):101–17.PubMedCrossRef
36.
McDevitt D, Francois PP, Vaudaux P, Foster TJ. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol Microbiol. 1994;11(2):237–48.PubMedCrossRef
37.
Wann ER, Gurusiddappa S, Hook M. The fibronectin-binding MSCRAMM FnbpA of Staphylococcus aureus is a bifunctional protein that also binds to fibrinogen. J Biol Chem. 2000;275(18):13863–71.PubMedCrossRef
38.
Downer R, Roche F, Park PW, Mecham RP, Foster TJ. The elastin-binding protein of Staphylococcus aureus (EbpS) is expressed at the cell surface as an integral membrane protein and not as a cell wall-associated protein. J Biol Chem. 2002;277(1):243–50.PubMedCrossRef
39.
Roche FM, Downer R, Keane F, Speziale P, Park PW, Foster TJ. The N-terminal A domain of fibronectin-binding proteins A and B promotes adhesion of Staphylococcus aureus to elastin. J Biol Chem. 2004;279(37):38433–40.PubMedCrossRef
40.
O’Brien LM, Walsh EJ, Massey RC, Peacock SJ, Foster TJ. Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cell Microbiol. 2002;4(11):759–70.PubMedCrossRef
41.
Que YA, François P, Haefliger JA, Entenza JM, Vaudaux P, Moreillon P. Reassessing the role of Staphylococcus aureus clumping factor and fibronectin-binding protein by expression in Lactococcus lactis. Infect Immun. 2001;69(10):6296–302.PubMedCrossRefPubMedCentral
42.
Fitzgerald JR, Loughman A, Keane F, Brennan M, Knobel M, Higgins J, et al. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor. Mol Microbiol. 2006;59(1):212–30.PubMedCrossRef
43.
Loughman A, Fitzgerald JR, Brennan MP, Higgins J, Downer R, Cox D, et al. Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol Microbiol. 2005;57(3):804–18.PubMedCrossRef
44.
Vanassche T, Verhaegen J, Peetermans WE, Hoylaerts MF, Verhamme P. Dabigatran inhibits Staphylococcus aureus coagulase activity. J Clin Microbiol. 2010;48(11):4248–50.PubMedCrossRefPubMedCentral
45.
Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008;83:536–45.PubMedCrossRef
46.
Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003;7:23–38.PubMedCrossRefPubMedCentral
47.
Henneke P, Golenbock DT. Innate immune recognition of lipopolysaccharide by endothelial cells. Crit Care Med. 2002;30:S207–13.PubMedCrossRef
48.
Zhang FX, Kirschning CJ, Mancinelli R, Xu XP, Jin YP, Faure E, et al. Bacterial lipopolysaccharide activates nuclear factor-κ B through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem. 1999;274:7611–4.PubMedCrossRef
49.
Akca S, Haji-Michael P, de Mendonca A, Suter P, Levi M, Vincent JL. Time course of platelet counts in critically ill patients. Crit Care Med. 2002;30:753–6.PubMedCrossRef
50.
Zielinski T, Wachowicz B, Saluk-Juszczak J, Kaca W. Polysaccharide part of Proteus mirabilis lipopolysaccharide may be responsible for the stimulation of platelet adhesion to collagen. Platelets. 2002;13:419–24.PubMedCrossRef
51.
Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002;30:S294–301.PubMedCrossRef
52.
Hamilton KK, Sims PJ. Changes in cytosolic Ca2+ associated with von Willebrand factor release in human endothelial cells exposed to histamine. Study of microcarrier cell monolayers using the fluorescent probe indo-1. J Clin Investig. 1987;79:600–8.PubMedCrossRefPubMedCentral
53.
54.
Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med. 2002;30:S302–12.PubMedCrossRef
55.
Cermak J, Key NS, Bach RR, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513–20.PubMed
56.
Durante Mangoni E, Adinolfi LE, Tripodi MF, Andreana A, Gambardella M, Ragone E, et al. Risk factors for ‘major’ embolic events in hospitalized patients with infective endocarditis. Am Heart J. 2003;146:55–61.CrossRef
57.•
Dickerman SA, Abrutyn E, Barsic B, et al. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J. 2007;154:1086–94. Prospective study on a representative patient dataset showing the effect of antimicrobial treatment on inflammatory markers and embolic risk. PubMedCrossRef
58.
Vigo C. Effect of C-reactive protein on platelet-activating factor induced platelet aggregation and membrane stabilization. J Biol Chem. 1985;260:3418–22.PubMed
59.
Fiedel BA, Simpson RM, Gewurz H. Effects of C-reactive protein (CRP) on platelet function. Ann NY Acad Sci. 1982;389:263–73.PubMedCrossRef
60.
Fiedel BA. Influence of tuftsin-like synthetic peptides derived from C-reactive protein (CRP) on platelet behaviour. Immunology. 1988;64:487–93.PubMedPubMedCentral
61.
Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001;85:639–46.PubMed
62.
63.
Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005;15:254–9.PubMedCrossRef
64.
Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109:2698–704.PubMedCrossRef
65.
Tleyjeh IM, Steckelberg JM, Murad HS, Anavekar NS, Ghomrawi HM, Mirzoyev Z, et al. Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota. JAMA. 2005;293(24):3022–8.PubMedCrossRef
66.
Duval X, Delahaye F, Alla F, Tattevin P, Obadia JF, Le Moing V, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol. 2012;59(22):1968–76.PubMedCrossRef
67.
Fedeli U, Schievano E, Buonfrate D, Pellizzer G, Spolaore P. Increasing incidence and mortality of infective endocarditis: a population-based study through a record-linkage system. BMC Infect Dis. 2011;11:48.PubMedCrossRefPubMedCentral
68.
69.
Kupferwasser LI, Hafner G, Mohr-Kahaly S, Erbel R, Meyer J, Darius H. The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events. J Am Coll Cardiol. 1999;33:1365–71.PubMedCrossRef
70.
Lopez LR, Hurley BL, Durante-Mangoni E, Simpson DF, Tripodi MF, Guardascione M, et al. Oxidative modification of low-density lipoprotein (LDL) and oxLDL/b2GPI complexes in patients with infectious endocarditis: possible role in aortic valve disease. J Thromb Haemost. 2005;3(Suppl. 1):abstr. #1881.
71.
Ileri M, Alper A, Senen K, Durmaz T, Atak R, Hisar I, et al. Effect of infective endocarditis on blood coagulation and platelet activation and comparison of patients with to those without embolic events. Am J Cardiol. 2003;91:689–92.PubMedCrossRef
72.
Buyukasýk NS, Ileri M, Alper A, Senen K, Atak R, Hisar I, et al. Increased blood coagulation and platelet activation in patients with infective endocarditis and embolic events. Clin Cardiol. 2004;27:154–8.PubMedCrossRef
73.
Mannucci PM. Venous thrombosis: the history of knowledge. Pathophysiol Haemost Thromb. 2002;32:209–12.PubMedCrossRef
74.
75.
Strong JP, Richards ML. Cigarette smoking and atherosclerosis in autopsied men. Atherosclerosis. 1976;23:451–76.PubMedCrossRef
76.
Di Micco P, D’Uva M. Editorial comment. To understand the two way clinical association between cancer and thrombophilia. Exp Oncol. 2003;25:243–4.
77.
Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia. Thromb Haemost. 1996; 76:651–62 (part I) & 824–34 (part II)
78.
Vossen CY, Conard J, Fontcuberta J, et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost. 2004;2:1526–33.PubMedCrossRef
79.
Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344:1222–31.PubMedCrossRef
80.
81.
Mannucci PM. Genetic hypercoagulability: prevention suggests testing family members. Blood. 2010;98:21–2.CrossRef
82.
De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood. 2006;87:3531.
83.
Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost. 2001;86:395–403.PubMed
84.
De Stefano V, Rossi E, Paciaroni K, et al. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica. 2002;87:1095–108.PubMed
85.
Bertina RM. Genetic approach to thrombophilia. J Endocrinol Investig. 2010;33(2):77–82.CrossRef
86.
Rosendaal FR, Helmerhost FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost. 2001;86:112–3.PubMed
87.
Korkmaz S, Ileri M, Hisar I, Yetkin E, Kosar F. Increased levels of soluble adhesion molecules, E-selectin and P-selectin, in patients with infective endocarditis and embolic events. Eur Heart J. 2001;22(10):874–8.PubMedCrossRef
88.
Durante-Mangoni E, Iossa D, Nappi F, et al. Inherited hyper-homocysteinemia as a cause of nonbacterial thrombotic endocarditis. J Heart Valve Dis. 2011;20:232–3.PubMed
89.
Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med. 2007;131:872–84.PubMed
Metadata
Title
The Role of Hemostasis in Infective Endocarditis
Authors
Emanuele Durante-Mangoni
Rosa Molaro
Domenico Iossa
Publication date
01-11-2014
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 11/2014
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-014-0435-8

Other articles of this Issue 11/2014

Current Infectious Disease Reports 11/2014 Go to the issue

Tropical, Travel and Emerging Infections (L Chen, Section Editor)

Recent Advances in Clinical Parasitology Diagnostics

Skin, Soft Tissue, Bone and Joint Infectious Diseases (N Safdar, Section Editor)

Mycobacterial Skin and Soft Tissue Infection

Central Nervous System Infections (J Lyons, Section Editor)

Spinal Epidural Abscess

Tropical, Travel and Emerging Infections (L Chen, Section Editor)

Neurocysticercosis: An Update

Cardiovascular Infections (D Levine, Section Editor)

Health Care-Associated Infective Endocarditis: a Growing Entity that Can Be Prevented

Cardiovascular Infections (D Levine, Section Editor)

Infective Endocarditis Epidemiology and Consequences of Prophylaxis Guidelines Modifications: the Dialectical Evolution
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits